New Vaccine Plan To Value Rs 50,000 Crore, Say Finance Ministry Sources


Talks with Pfizer and Moderna are reportedly caught on the indemnity demand by the vaccine makers.

New Delhi:

A day after Prime Minister Narendra Modi introduced that the Centre is taking again vaccine-buying from states, the Finance Ministry mentioned the programme will value round Rs 50,000 crore and the federal government has the cash.

“We needn’t go for the supplementary grants instantly as there are sufficient funds. We might should go for this within the second spherical, close to the winter session of Parliament. At current we’ve the cash,” Finance Ministry sources mentioned.

The sources additionally indicated that the federal government is not relying on international vaccines to satisfy its vaccine wants.

“Our programme of procurement is centred round Bharat Biotech, Serum Institute and the brand new Bio-E; we will provide vaccines for the substantial inhabitants from these vaccines,” sources mentioned.

Talks with Pfizer and Moderna are reportedly caught on the indemnity demand by the vaccine makers and their insistence that disputes in India associated to their vaccines be taken up in US courts solely.

“At current Moderna has no plan to enter until January subsequent 12 months,” mentioned Finance Ministry sources.

Moreover Bharat Biotech’s Covaxin and Serum Institute of India’s Covishield, Russia’s Sputnik V has been cleared to be used within the nation.

However Sputnik “is not going to be substantial” in quantity, mentioned officers, including, “We’ve not began procurement for this nonetheless.”

The federal government final week mentioned it has booked 30 crore doses of Hyderabad-based Organic-E’s Covid vaccine, which remains to be in medical trials. The Well being Ministry will make an advance fee of Rs 1,500 crore to the corporate for what would be the second made-in-India vaccine after Covaxin.

The Supreme Court docket had final week requested the Centre to supply particulars of all vaccine purchases made thus far.

Authorities sources at this time mentioned from January to thirty first July, a complete of 53.6 crore vaccine doses shall be obtainable to be used. The Centre purchased 12 crore vaccine doses between March and Could at a price of Rs 1,890 crore. One other 16 crore doses of vaccine had been ordered on Could 5  — for Could, June and July — for Rs 2,520 crore, sources mentioned.

The funds for each purchases had been drawn from the Price range, sources mentioned. Rs 150 was added to the price of every vaccine dose on account of GST or Items and Companies tax, sources mentioned.

Moreover, 6.6 crore doses had been bought from the PM-CARES Fund. These embrace 5.6 million doses of Covishield and 10 million doses of Covaxin. For this, Rs 1,392.825 crore was paid, sources mentioned.

States, union territories and personal hospitals additionally made direct buy of the vaccine – which added as much as 18 crore doses of Covishield, 5 crore doses of Covaxin and 20 million doses of Sputnik V.

As well as, 10 million doses of Covishield had been obtained from the Gavi Covax facility, which have already been put into use.

Finance Ministry sources additionally spoke about Dearness Allowance to central authorities workers and mentioned the choice is to offer it from July 1 “prospectively and never retrospectively with arrears”.

“We will not have each free vaccine and enhance in Dearness Allowance with retrospective impact. We now have to prioritise and resolve what’s extra necessary,” officers mentioned.